At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 36 enrolled
Drug / intervention
Histrelin Subcutaneous Implantdrug
Likely dose
Histrelin Subcutaneous Implant 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase III, Open-Label Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Children With Central Precocious Puberty
In Brief
A Phase 3 clinical trial evaluating Histrelin Subcutaneous Implant for Central Precocious Puberty. Completed, enrolled 36 participants.
Detailed Summary
The purpose of this study is to follow and collect additional medical and developmental information on children after histrelin subcutaneous implant therapy is discontinued.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCentral Precocious Puberty
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2004
First PostedOct 2008
Primary CompletionAug 2011
Study CompletionApr 2012
TodayJul 2026
First PostedOct 24, 2008
Enrollment StartSep 1, 2004
Primary CompletionAug 1, 2011
Study CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 17.7 years ago
Interventions
Histrelin Subcutaneous Implantdrug
histrelin subcutaneous 50 mg implant